<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>KRAS mutation status has a significant role determining anti-epidermal growth factor receptor (anti-EGFR) treatment response in colon <z:mp ids='MP_0002038'>carcinoma</z:mp> patients </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">Malignant transformation</z:e> is a dynamic process and therefore, it is conceivable that, at a certain point, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells' mass might be <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> for particular mutations </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, the fraction of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells carrying a particular mutation may be more relevant for treatment than the simple determination of presence or absence of mutation </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this study is to assess whether or not KRAS mutation status is <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> and, if so, to what extent in colon <z:mp ids='MP_0002038'>carcinoma</z:mp> samples </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="9" ids="16991">Deoxyribonucleic acid</z:chebi> was extracted from formalin-fixed paraffin-embedded samples of colon <z:mp ids='MP_0002038'>carcinoma</z:mp> and analyzed for the presence of KRAS mutation </plain></SENT>
<SENT sid="5" pm="."><plain>The relative fraction of mutated versus <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS alleles was evaluated by real-time polymerase chain reaction </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, the relative fraction of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells in the tissue sample was evaluated using computer assisted morphometric analysis </plain></SENT>
<SENT sid="7" pm="."><plain>Using this data, we calculated the fraction of mutation containing cells in the samples </plain></SENT>
<SENT sid="8" pm="."><plain>Colon <z:mp ids='MP_0002038'>carcinoma</z:mp> (169 cases) were analyzed, and a KRAS mutation was found in 75 cases (44%), of which 42 were available for morphometric analysis </plain></SENT>
<SENT sid="9" pm="."><plain>In 41 (97.6%) of these cases, the fraction of mutation containing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells was 50% or higher, indicating the absence of significant KRAS mutation status <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>There was a strong positive correlation (R = 0.66, P &lt; 0.0001) between the fraction of mutated KRAS alleles and the fraction of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells in the samples </plain></SENT>
<SENT sid="11" pm="."><plain>The strong positive correlation between the fraction of mutated KRAS alleles and the fraction of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells in the samples indicate homogeneity of KRAS mutation status in colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
</text></document>